A2bAR activation ameliorates a diabetic profile.

<p>Glucose parameters were measured in WT mice 20 weeks post HFD (32 weeks of age), in the last 4 weeks (of the 20) administration of A2bAR specific agonist BAY 60-6583 (denoted as BAY) or Vehicle (denoted as Vehicle) was introduced, following a regime described in Methods. The following parameters were measured: <b>A.</b> Blood glucose levels (n = 12/group), p-value = 0.0178. <b>B.</b> Insulin levels (n = 8/group). <b>C.</b> Glucose clearance in the blood post glucose overload (n = 12/group), p-value = 0.0178 (0 min); 0.0198 (30 min); 0.0163 (45 min); 0.0061 (60 min); 0.0346 (90 min). <b>D.</b> Glucose clearance in the plasma as a result of insulin overload (n = 8/group) 6 hours post starvation, graphed as percentage of baseline, p-values = 0.0085 (30 min); 0.0005 (60 min); 0.0248 (90 min); 0.0176 (120 min). <b>E.</b> Western blot analysis of hepatic IRS-2 levels post-Bay 60-6583 injection. <b>F.</b> Fat to Lean Mass Ratio 4 weeks post-Bay 60-6583 administration, p-value = 0.0227. <b>G.</b> Percent weight gain with 4 weeks BAY treatment, p-values = 0.0026 (day 15); 0.0061 (day 18); 0.0078 (day 21); 0.0017 (day 24); 0.0065 (day 28), respectively.